drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00280 | DB00377 | 494 | 1,494 | [
"DDInter575",
"DDInter1382"
] | Disopyramide | Palonosetron | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Major | 2 | [
[
[
494,
25,
1494
]
],
[
[
494,
6,
8374
],
[
8374,
45,
1494
]
],
[
[
494,
21,
29240
],
[
29240,
60,
1494
]
],
[
[
494,
23,
112
],
[
112,
... | [
[
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palonosetron"
]
],
[
[
"Disopyramide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"P... | Disopyramide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Palonosetron (Compound)
Disopyramide (Compound) causes Feeling hot (Side Effect) and Feeling hot (Side Effect) is caused by Palonosetron (Compound)
Disopyramide may cause a minor interaction that can limit clinical effects when taken with Metroni... |
DB00603 | DB11827 | 303 | 433 | [
"DDInter1137",
"DDInter669"
] | Medroxyprogesterone acetate | Ertugliflozin | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
303,
24,
433
]
],
[
[
303,
24,
1654
],
[
1654,
63,
433
]
],
[
[
303,
63,
695
],
[
695,
24,
433
]
],
[
[
303,
24,
959
],
[
959,
2... | [
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}... | Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan and Somapacitan may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate disease... |
DB00574 | DB01227 | 121 | 1,301 | [
"DDInter717",
"DDInter1043"
] | Fenfluramine | Levacetylmethadol | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well... | Moderate | 1 | [
[
[
121,
24,
1301
]
],
[
[
121,
63,
576
],
[
576,
1,
1301
]
],
[
[
121,
25,
939
],
[
939,
1,
1301
]
],
[
[
121,
24,
144
],
[
144,
63... | [
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levacetylmethadol"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methadone"
]... | Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone (Compound) resembles Levacetylmethadol (Compound)
Fenfluramine may lead to a major life threatening interaction when taken with Benzphetamine and Benzphetamine (Compound) resembles Levacetylmethadol (Com... |
DB00818 | DB11901 | 898 | 913 | [
"DDInter1538",
"DDInter107"
] | Propofol | Apalutamide | Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associate... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
898,
24,
913
]
],
[
[
898,
23,
112
],
[
112,
23,
913
]
],
[
[
898,
63,
600
],
[
600,
24,
913
]
],
[
[
898,
24,
28
],
[
28,
24,
... | [
[
[
"Propofol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Propofol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Propofol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Propofol may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Flucon... |
DB00214 | DB00741 | 1,028 | 167 | [
"DDInter1836",
"DDInter885"
] | Torasemide | Hydrocortisone | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Moderate | 1 | [
[
[
1028,
24,
167
]
],
[
[
1028,
24,
1220
],
[
1220,
40,
167
]
],
[
[
1028,
24,
870
],
[
870,
1,
167
]
],
[
[
1028,
6,
3486
],
[
3486,
... | [
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Hydrocortisone (Compound)
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Hy... |
DB00213 | DB00682 | 837 | 126 | [
"DDInter1388",
"DDInter1951"
] | Pantoprazole | Warfarin | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zolling... | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Moderate | 1 | [
[
[
837,
24,
126
]
],
[
[
837,
24,
1335
],
[
1335,
40,
126
]
],
[
[
837,
6,
7950
],
[
7950,
45,
126
]
],
[
[
837,
62,
168
],
[
168,
... | [
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
]
],
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
],
... | Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine (Compound) resembles Warfarin (Compound)
Pantoprazole (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Warfarin (Compound)
Pantoprazole may cause a minor interaction that can limit cl... |
DB00586 | DB08827 | 1,512 | 990 | [
"DDInter537",
"DDInter1085"
] | Diclofenac | Lomitapide | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Major | 2 | [
[
[
1512,
25,
990
]
],
[
[
1512,
6,
8374
],
[
8374,
45,
990
]
],
[
[
1512,
21,
28701
],
[
28701,
60,
990
]
],
[
[
1512,
25,
1409
],
[
1409... | [
[
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
],
[
[
"Diclofenac",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Lomitap... | Diclofenac (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lomitapide (Compound)
Diclofenac (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Lomitapide (Compound)
Diclofenac may lead to a major life threatening interaction when taken with Apixaban and Apixaban may cause ... |
DB00041 | DB01044 | 1,648 | 246 | [
"DDInter38",
"DDInter809"
] | Aldesleukin | Gatifloxacin | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatiflox... | Minor | 0 | [
[
[
1648,
23,
246
]
],
[
[
1648,
23,
739
],
[
739,
1,
246
]
],
[
[
1648,
23,
945
],
[
945,
40,
246
]
],
[
[
1648,
24,
377
],
[
377,
... | [
[
[
"Aldesleukin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Aldesleukin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
],
[
... | Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Gatifloxacin (Compound)
Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Gatifloxacin (... |
DB01023 | DB09133 | 409 | 1,527 | [
"DDInter716",
"DDInter965"
] | Felodipine | Iothalamic acid | Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte... | Iothalamic acid is an iodine containing organic anion used as a diagnostic contrast agent. | Moderate | 1 | [
[
[
409,
24,
1527
]
],
[
[
409,
24,
278
],
[
278,
63,
1527
]
],
[
[
409,
40,
84
],
[
84,
24,
1527
]
],
[
[
409,
1,
336
],
[
336,
24,... | [
[
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iothalamic acid"
]
],
[
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
],
... | Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid and Iopodic acid may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid
Felodipine (Compound) resembles Nisoldipine (Compound) and Nisoldipine may cause a moderate interaction... |
DB00877 | DB01118 | 629 | 33 | [
"DDInter1678",
"DDInter76"
] | Sirolimus | Amiodarone | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Moderate | 1 | [
[
[
629,
24,
33
]
],
[
[
629,
24,
540
],
[
540,
1,
33
]
],
[
[
629,
6,
6799
],
[
6799,
45,
33
]
],
[
[
629,
18,
8733
],
[
8733,
46,
... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
],
[
... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone and Dronedarone (Compound) resembles Amiodarone (Compound)
Sirolimus (Compound) binds CYP3A7 (Gene) and CYP3A7 (Gene) is bound by Amiodarone (Compound)
Sirolimus (Compound) downregulates PHGDH (Gene) and PHGDH (Gene) i... |
DB01259 | DB09330 | 392 | 985 | [
"DDInter1024",
"DDInter1352"
] | Lapatinib | Osimertinib | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
392,
25,
985
]
],
[
[
392,
62,
1247
],
[
1247,
23,
985
]
],
[
[
392,
63,
608
],
[
608,
23,
985
]
],
[
[
392,
24,
1478
],
[
1478,
... | [
[
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Lapatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfame... | Lapatinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and ... |
DB00004 | DB08895 | 669 | 976 | [
"DDInter499",
"DDInter1825"
] | Denileukin diftitox | Tofacitinib | A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system. | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
669,
25,
976
]
],
[
[
669,
24,
200
],
[
200,
63,
976
]
],
[
[
669,
24,
1430
],
[
1430,
24,
976
]
],
[
[
669,
25,
1011
],
[
1011,
... | [
[
[
"Denileukin diftitox",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Denileukin diftitox",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]... | Denileukin diftitox may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Denileukin diftitox may cause a moderate interaction that could exacerbate diseases when t... |
DB00193 | DB09472 | 534 | 1,383 | [
"DDInter1841",
"DDInter1693"
] | Tramadol | Sodium sulfate | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
534,
24,
1383
]
],
[
[
534,
25,
678
],
[
678,
24,
1383
]
],
[
[
534,
24,
609
],
[
609,
24,
1383
]
],
[
[
534,
63,
521
],
[
521,
... | [
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxamniquine"
],
[
"Oxamniqui... | Tramadol may lead to a major life threatening interaction when taken with Oxamniquine and Oxamniquine may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin ... |
DB11828 | DB11853 | 1,406 | 230 | [
"DDInter1281",
"DDInter1577"
] | Neratinib | Relugolix | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under th... | Major | 2 | [
[
[
1406,
25,
230
]
],
[
[
1406,
64,
129
],
[
129,
23,
230
]
],
[
[
1406,
63,
1456
],
[
1456,
24,
230
]
],
[
[
1406,
25,
1017
],
[
1017,
... | [
[
[
"Neratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Relugolix"
]
],
[
[
"Neratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} ... | Neratinib may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Venetoclax may cause a... |
DB00358 | DB00738 | 1,010 | 485 | [
"DDInter1140",
"DDInter1420"
] | Mefloquine | Pentamidine | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Moderate | 1 | [
[
[
1010,
24,
485
]
],
[
[
1010,
6,
12523
],
[
12523,
45,
485
]
],
[
[
1010,
7,
8733
],
[
8733,
46,
485
]
],
[
[
1010,
7,
9650
],
[
9650,
... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
]
],
[
[
"Mefloquine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)"... | Mefloquine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pentamidine (Compound)
Mefloquine (Compound) upregulates PHGDH (Gene) and PHGDH (Gene) is upregulated by Pentamidine (Compound)
Mefloquine (Compound) upregulates HMGCS1 (Gene) and HMGCS1 (Gene) is downregulated by Pentamidine (Compound)
Mefloquine ... |
DB00242 | DB01024 | 1,064 | 1,096 | [
"DDInter392",
"DDInter1252"
] | Cladribine | Mycophenolic acid | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | Major | 2 | [
[
[
1064,
25,
1096
]
],
[
[
1064,
25,
955
],
[
955,
1,
1096
]
],
[
[
1064,
7,
18134
],
[
18134,
46,
1096
]
],
[
[
1064,
18,
18560
],
[
185... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mycophenolate mofetil"
],
[
"Mycophe... | Cladribine may lead to a major life threatening interaction when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) resembles Mycophenolic acid (Compound)
Cladribine (Compound) upregulates POLD4 (Gene) and POLD4 (Gene) is upregulated by Mycophenolic acid (Compound)
Cladribine (Compound) downregulates... |
DB01019 | DB01409 | 427 | 1,415 | [
"DDInter199",
"DDInter1815"
] | Bethanechol | Tiotropium | Bethanechol is a synthetic ester that was initially synthesized in 1935.[A232905,L32539] As a cholinergic agent, bethanechol is similar in structure and pharmacological function to acetylcholine and is used in specific cases when stimulation of the parasympathetic nervous system is necessary.[A232905,L32539] For exampl... | Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma.[A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.[A180163,L7084,L... | Moderate | 1 | [
[
[
427,
24,
1415
]
],
[
[
427,
6,
4304
],
[
4304,
45,
1415
]
],
[
[
427,
21,
28900
],
[
28900,
60,
1415
]
],
[
[
427,
63,
1528
],
[
1528,... | [
[
[
"Bethanechol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiotropium"
]
],
[
[
"Bethanechol",
"{u} (Compound) binds {v} (Gene)",
"CHRM2"
],
[
"CHRM2",
"{u} (Gene) is bound by {v} (Compound)",... | Bethanechol (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Tiotropium (Compound)
Bethanechol (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Tiotropium (Compound)
Bethanechol may cause a moderate interaction that could exacerbate diseases when taken with Physosti... |
DB00376 | DB00782 | 1,105 | 1,123 | [
"DDInter1870",
"DDInter1535"
] | Trihexyphenidyl | Propantheline | Trihexyphenidyl is a centrally acting muscarinic antagonist used for treatment of parkinsonism and drug-induced extrapyramidal disorders.[L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity. Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is n... | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | Moderate | 1 | [
[
[
1105,
24,
1123
]
],
[
[
1105,
6,
7992
],
[
7992,
45,
1123
]
],
[
[
1105,
21,
28898
],
[
28898,
60,
1123
]
],
[
[
1105,
24,
537
],
[
53... | [
[
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
]
],
[
[
"Trihexyphenidyl",
"{u} (Compound) binds {v} (Gene)",
"CHRM1"
],
[
"CHRM1",
"{u} (Gene) is bound by {v} (... | Trihexyphenidyl (Compound) binds CHRM1 (Gene) and CHRM1 (Gene) is bound by Propantheline (Compound)
Trihexyphenidyl (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Propantheline (Compound)
Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken... |
DB00307 | DB00471 | 1,101 | 201 | [
"DDInter202",
"DDInter1242"
] | Bexarotene | Montelukast | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Although capable of demonstrating effectiveness, the use of such LTRAs like montel... | Moderate | 1 | [
[
[
1101,
24,
201
]
],
[
[
1101,
6,
6017
],
[
6017,
45,
201
]
],
[
[
1101,
21,
29203
],
[
29203,
60,
201
]
],
[
[
1101,
23,
1017
],
[
1017... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Montelukast"
]
],
[
[
"Bexarotene",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)"... | Bexarotene (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Montelukast (Compound)
Bexarotene (Compound) causes Aspartate aminotransferase increased (Side Effect) and Aspartate aminotransferase increased (Side Effect) is caused by Montelukast (Compound)
Bexarotene may cause a minor interaction that can limi... |
DB00262 | DB01030 | 552 | 869 | [
"DDInter302",
"DDInter1835"
] | Carmustine | Topotecan | A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogen... | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Moderate | 1 | [
[
[
552,
24,
869
]
],
[
[
552,
21,
29276
],
[
29276,
60,
869
]
],
[
[
552,
23,
872
],
[
872,
62,
869
]
],
[
[
552,
23,
1467
],
[
1467,
... | [
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Carmustine",
"{u} (Compound) causes {v} (Side Effect)",
"Haemoglobin"
],
[
"Haemoglobin",
"{u} (Side Effect) is c... | Carmustine (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Topotecan (Compound)
Carmustine may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin and Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Topo... |
DB00358 | DB08865 | 1,010 | 1,593 | [
"DDInter1140",
"DDInter448"
] | Mefloquine | Crizotinib | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
1010,
25,
1593
]
],
[
[
1010,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
1010,
7,
9650
],
[
9650,
46,
1593
]
],
[
[
1010,
7,
8733
],
[
8733,... | [
[
[
"Mefloquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Mefloquine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Crizoti... | Mefloquine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Mefloquine (Compound) upregulates HMGCS1 (Gene) and HMGCS1 (Gene) is upregulated by Crizotinib (Compound)
Mefloquine (Compound) upregulates PHGDH (Gene) and PHGDH (Gene) is downregulated by Crizotinib (Compound)
Mefloquine (Co... |
DB00683 | DB06372 | 1,382 | 259 | [
"DDInter1212",
"DDInter1594"
] | Midazolam | Rilonacept | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazola... | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Moderate | 1 | [
[
[
1382,
24,
259
]
],
[
[
1382,
24,
1619
],
[
1619,
63,
259
]
],
[
[
1382,
1,
1565
],
[
1565,
24,
259
]
],
[
[
1382,
62,
1573
],
[
1573,
... | [
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
... | Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Midazolam (Compound) resembles Clonazepam (Compound) and Clonazepam may cause a moderate interaction that could exa... |
DB01259 | DB01589 | 392 | 481 | [
"DDInter1024",
"DDInter1552"
] | Lapatinib | Quazepam | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Quazepam is a trifluoroethyl benzodiazepine derivative. It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors a... | Moderate | 1 | [
[
[
392,
24,
481
]
],
[
[
392,
63,
1216
],
[
1216,
1,
481
]
],
[
[
392,
6,
10215
],
[
10215,
45,
481
]
],
[
[
392,
21,
28757
],
[
28757,
... | [
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
],
[
... | Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Quazepam (Compound)
Lapatinib (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Quazepam (Compound)
Lapatinib (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Sid... |
DB00218 | DB01168 | 1,176 | 1,053 | [
"DDInter1247",
"DDInter1526"
] | Moxifloxacin | Procarbazine | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Minor | 0 | [
[
[
1176,
23,
1053
]
],
[
[
1176,
24,
848
],
[
848,
40,
1053
]
],
[
[
1176,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
1176,
1,
246
],
[
246,... | [
[
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Procarbazine"
]
],
[
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[... | Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen (Compound) resembles Procarbazine (Compound)
Moxifloxacin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Moxifloxacin (Compound) resembles Gatifl... |
DB11767 | DB11793 | 1,583 | 738 | [
"DDInter1643",
"DDInter1297"
] | Sarilumab | Niraparib | Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approve... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
1583,
24,
738
]
],
[
[
1583,
63,
663
],
[
663,
24,
738
]
],
[
[
1583,
24,
1129
],
[
1129,
63,
738
]
],
[
[
1583,
64,
1184
],
[
1184,
... | [
[
[
"Sarilumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Sarilumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
... | Sarilumab may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Sarilumab may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e s... |
DB00418 | DB01142 | 536 | 1,264 | [
"DDInter1650",
"DDInter593"
] | Secobarbital | Doxepin | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
536,
24,
1264
]
],
[
[
536,
24,
401
],
[
401,
24,
1264
]
],
[
[
536,
63,
1594
],
[
1594,
24,
1264
]
],
[
[
536,
24,
649
],
[
649,
... | [
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[... | Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and D... |
DB00446 | DB08815 | 597 | 154 | [
"DDInter351",
"DDInter1104"
] | Chloramphenicol | Lurasidone | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Moderate | 1 | [
[
[
597,
24,
154
]
],
[
[
597,
6,
8374
],
[
8374,
45,
154
]
],
[
[
597,
21,
28809
],
[
28809,
60,
154
]
],
[
[
597,
24,
1619
],
[
1619,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
]
],
[
[
"Chloramphenicol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (C... | Chloramphenicol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lurasidone (Compound)
Chloramphenicol (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Lurasidone (Compound)
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Ruca... |
DB00399 | DB01362 | 963 | 497 | [
"DDInter1968",
"DDInter960"
] | Zoledronic acid | Iohexol | Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to [ibandronic acid], [minodronic acid], and [risedronic acid]. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors,... | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Major | 2 | [
[
[
963,
25,
497
]
],
[
[
963,
25,
258
],
[
258,
40,
497
]
],
[
[
963,
21,
28681
],
[
28681,
60,
497
]
],
[
[
963,
24,
50
],
[
50,
2... | [
[
[
"Zoledronic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Zoledronic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iodixanol"
],
[
"Iodixanol",
"... | Zoledronic acid may lead to a major life threatening interaction when taken with Iodixanol and Iodixanol (Compound) resembles Iohexol (Compound)
Zoledronic acid (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Iohexol (Compound)
Zoledronic acid may cause a moderate intera... |
DB01174 | DB09030 | 697 | 840 | [
"DDInter1442",
"DDInter1945"
] | Phenobarbital | Vorapaxar | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Major | 2 | [
[
[
697,
25,
840
]
],
[
[
697,
25,
765
],
[
765,
24,
840
]
],
[
[
697,
25,
1017
],
[
1017,
63,
840
]
],
[
[
697,
63,
1061
],
[
1061,
... | [
[
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
]
],
[
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hemin"
],
[
"Hemin",
"{u} may ca... | Phenobarbital may lead to a major life threatening interaction when taken with Hemin and Hemin may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar
Phenobarbital may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interacti... |
DB06810 | DB14357 | 397 | 944 | [
"DDInter1484",
"DDInter347"
] | Plicamycin | Chamomile | Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000. | Chamomile is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug. | Minor | 0 | [
[
[
397,
23,
944
]
],
[
[
397,
64,
256
],
[
256,
23,
944
]
],
[
[
397,
25,
498
],
[
498,
23,
944
]
],
[
[
397,
63,
1061
],
[
1061,
2... | [
[
[
"Plicamycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
]
],
[
[
"Plicamycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
],
[
"Prasugrel",
... | Plicamycin may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Chamomile
Plicamycin may lead to a major life threatening interaction when taken with Edoxaban and Edoxaban may cause a minor interaction that... |
DB05773 | DB06414 | 1,047 | 655 | [
"DDInter1848",
"DDInter703"
] | Trastuzumab emtansine | Etravirine | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Moderate | 1 | [
[
[
1047,
24,
655
]
],
[
[
1047,
63,
168
],
[
168,
23,
655
]
],
[
[
1047,
64,
477
],
[
477,
24,
655
]
],
[
[
1047,
25,
1409
],
[
1409,
... | [
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Borte... | Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Etravirine
Trastuzumab emtansine may lead to a major life threatening interaction when taken with Cilostazol and C... |
DB00970 | DB11793 | 0 | 738 | [
"DDInter466",
"DDInter1297"
] | Dactinomycin | Niraparib | A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also d... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
0,
24,
738
]
],
[
[
0,
63,
1253
],
[
1253,
24,
738
]
],
[
[
0,
24,
496
],
[
496,
24,
738
]
],
[
[
0,
25,
770
],
[
770,
24,
... | [
[
[
"Dactinomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Dactinomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palifermin"
],
[... | Dactinomycin may cause a moderate interaction that could exacerbate diseases when taken with Palifermin and Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Dactinomycin may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccin... |
DB00539 | DB08881 | 11 | 868 | [
"DDInter1837",
"DDInter1925"
] | Toremifene | Vemurafenib | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Major | 2 | [
[
[
11,
25,
868
]
],
[
[
11,
6,
8374
],
[
8374,
45,
868
]
],
[
[
11,
7,
7972
],
[
7972,
46,
868
]
],
[
[
11,
7,
6886
],
[
6886,
57,
... | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Toremifene",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Vemura... | Toremifene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Toremifene (Compound) upregulates COL11A1 (Gene) and COL11A1 (Gene) is upregulated by Vemurafenib (Compound)
Toremifene (Compound) upregulates MSMO1 (Gene) and MSMO1 (Gene) is downregulated by Vemurafenib (Compound)
Toremifen... |
DB00041 | DB00467 | 1,648 | 1,467 | [
"DDInter38",
"DDInter644"
] | Aldesleukin | Enoxacin | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. | Minor | 0 | [
[
[
1648,
23,
1467
]
],
[
[
1648,
23,
1539
],
[
1539,
40,
1467
]
],
[
[
1648,
23,
1299
],
[
1299,
1,
1467
]
],
[
[
1648,
24,
1686
],
[
168... | [
[
[
"Aldesleukin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enoxacin"
]
],
[
[
"Aldesleukin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ofloxacin"
],
[
"... | Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Ofloxacin and Ofloxacin (Compound) resembles Enoxacin (Compound)
Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin and Trovafloxacin (Compound) resembles Enoxacin (Compound)
Al... |
DB00349 | DB00719 | 902 | 1,219 | [
"DDInter401",
"DDInter149"
] | Clobazam | Azatadine | Clobazam belongs to the 1,5-benzodiazepine class of drugs and is marketed under different names, Onfi, Frisium, Urbanyl, and others.. Clobazam was first synthesized in 1966 and first published in 1969, following the incidental synthesis and discovery of the first benzodiazepine chlordiazepoxide in the 1950s. Unlike old... | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Moderate | 1 | [
[
[
902,
24,
1219
]
],
[
[
902,
24,
13
],
[
13,
24,
1219
]
],
[
[
902,
24,
830
],
[
830,
1,
1219
]
],
[
[
902,
40,
695
],
[
695,
24,... | [
[
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
]
],
[
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
... | Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine
Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and P... |
DB01610 | DB08880 | 248 | 1,510 | [
"DDInter1912",
"DDInter1771"
] | Valganciclovir | Teriflunomide | Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Moderate | 1 | [
[
[
248,
24,
1510
]
],
[
[
248,
40,
563
],
[
563,
24,
1510
]
],
[
[
248,
63,
10
],
[
10,
24,
1510
]
],
[
[
248,
24,
36
],
[
36,
25,
... | [
[
[
"Valganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
]
],
[
[
"Valganciclovir",
"{u} (Compound) resembles {v} (Compound)",
"Ganciclovir"
],
[
"Ganciclovir",
"{u} may ca... | Valganciclovir (Compound) resembles Ganciclovir (Compound) and Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction tha... |
DB00495 | DB00738 | 139 | 485 | [
"DDInter1961",
"DDInter1420"
] | Zidovudine | Pentamidine | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain... | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Moderate | 1 | [
[
[
139,
24,
485
]
],
[
[
139,
6,
8374
],
[
8374,
45,
485
]
],
[
[
139,
21,
29191
],
[
29191,
60,
485
]
],
[
[
139,
24,
1272
],
[
1272,
... | [
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
]
],
[
[
"Zidovudine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Zidovudine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pentamidine (Compound)
Zidovudine (Compound) causes Vasculitis (Side Effect) and Vasculitis (Side Effect) is caused by Pentamidine (Compound)
Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Flucytosine and... |
DB00497 | DB14724 | 828 | 48 | [
"DDInter1366",
"DDInter634"
] | Oxycodone | Emapalumab | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018.[A38676, L4840] The approval of emapalumab was followed by the designation of orphan drug, priority... | Moderate | 1 | [
[
[
828,
24,
48
]
],
[
[
828,
6,
12523
],
[
12523,
45,
1463
],
[
1463,
24,
48
]
],
[
[
828,
21,
28748
],
[
28748,
60,
1463
],
[
1463,
24... | [
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Emapalumab"
]
],
[
[
"Oxycodone",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
... | Oxycodone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Lovastatin (Compound) and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Emapalumab
Oxycodone (Compound) causes Vertigo (Side Effect) and Vertigo (Side Effect) is caused by Lovastatin (Compound) and Lovast... |
DB08871 | DB11837 | 36 | 1,297 | [
"DDInter666",
"DDInter1351"
] | Eribulin | Osilodrostat | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
36,
24,
1297
]
],
[
[
36,
63,
112
],
[
112,
23,
1297
]
],
[
[
36,
62,
1247
],
[
1247,
23,
1297
]
],
[
[
36,
63,
623
],
[
623,
24... | [
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
... | Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Eribulin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and ... |
DB12267 | DB12332 | 1,476 | 1,619 | [
"DDInter233",
"DDInter1626"
] | Brigatinib | Rucaparib | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
1476,
24,
1619
]
],
[
[
1476,
64,
307
],
[
307,
23,
1619
]
],
[
[
1476,
62,
1135
],
[
1135,
23,
1619
]
],
[
[
1476,
24,
907
],
[
907,
... | [
[
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Brigatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Modafinil"
],
[
"Modafinil",
... | Brigatinib may lead to a major life threatening interaction when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Brigatinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor i... |
DB00370 | DB00692 | 1,251 | 274 | [
"DDInter1230",
"DDInter1448"
] | Mirtazapine | Phentolamine | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6... | Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine.[... | Moderate | 1 | [
[
[
1251,
24,
274
]
],
[
[
1251,
6,
5372
],
[
5372,
45,
274
]
],
[
[
1251,
21,
29118
],
[
29118,
60,
274
]
],
[
[
1251,
24,
530
],
[
530,
... | [
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentolamine"
]
],
[
[
"Mirtazapine",
"{u} (Compound) binds {v} (Gene)",
"ADRA2A"
],
[
"ADRA2A",
"{u} (Gene) is bound by {v} (Compoun... | Mirtazapine (Compound) binds ADRA2A (Gene) and ADRA2A (Gene) is bound by Phentolamine (Compound)
Mirtazapine (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Phentolamine (Compound)
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Dronabin... |
DB00060 | DB00175 | 912 | 681 | [
"DDInter947",
"DDInter1509"
] | Interferon beta-1a | Pravastatin | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Pravastatin is the 6-alpha-hydroxy acid form of [mevastatin]. Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. It was the first statin administered as the active form and not as a prodrug. This drug was developed by Sankyo Co. Ltd.; however, the first approved pravasta... | Moderate | 1 | [
[
[
912,
24,
681
]
],
[
[
912,
24,
1463
],
[
1463,
40,
681
]
],
[
[
912,
24,
126
],
[
126,
62,
681
]
],
[
[
912,
24,
322
],
[
322,
6... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pravastatin"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lovastatin... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Lovastatin and Lovastatin (Compound) resembles Pravastatin (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction ... |
DB00619 | DB06372 | 1,419 | 259 | [
"DDInter909",
"DDInter1594"
] | Imatinib | Rilonacept | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Moderate | 1 | [
[
[
1419,
24,
259
]
],
[
[
1419,
24,
0
],
[
0,
24,
259
]
],
[
[
1419,
24,
1619
],
[
1619,
63,
259
]
],
[
[
1419,
25,
1456
],
[
1456,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dactinomycin"
],
[
... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Dactinomycin and Dactinomycin may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucapar... |
DB00529 | DB13074 | 789 | 877 | [
"DDInter779",
"DDInter1110"
] | Foscarnet | Macimorelin | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Major | 2 | [
[
[
789,
25,
877
]
],
[
[
789,
23,
112
],
[
112,
23,
877
]
],
[
[
789,
24,
913
],
[
913,
24,
877
]
],
[
[
789,
63,
251
],
[
251,
24,... | [
[
[
"Foscarnet",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Foscarnet",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidaz... | Foscarnet may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apal... |
DB01041 | DB11601 | 770 | 1,270 | [
"DDInter1789",
"DDInter1889"
] | Thalidomide | Tuberculin purified protein derivative | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
770,
24,
1270
]
],
[
[
770,
24,
350
],
[
350,
24,
1270
]
],
[
[
770,
64,
550
],
[
550,
24,
1270
]
],
[
[
770,
63,
13
],
[
13,
24... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Thalidomide may lead to a major life threatening interaction when taken with Tras... |
DB00889 | DB11853 | 1,133 | 230 | [
"DDInter840",
"DDInter1577"
] | Granisetron | Relugolix | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under th... | Moderate | 1 | [
[
[
1133,
24,
230
]
],
[
[
1133,
24,
129
],
[
129,
23,
230
]
],
[
[
1133,
23,
112
],
[
112,
23,
230
]
],
[
[
1133,
63,
1101
],
[
1101,
... | [
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
]
],
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[... | Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Granisetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Me... |
DB00078 | DB14357 | 1,172 | 944 | [
"DDInter898",
"DDInter347"
] | Ibritumomab tiuxetan | Chamomile | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light... | Chamomile is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug. | Minor | 0 | [
[
[
1172,
23,
944
]
],
[
[
1172,
25,
256
],
[
256,
23,
944
]
],
[
[
1172,
64,
582
],
[
582,
23,
944
]
],
[
[
1172,
24,
578
],
[
578,
... | [
[
[
"Ibritumomab tiuxetan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
],
[
... | Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Chamomile
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Reteplase and Reteplase may cause a ... |
DB09038 | DB09272 | 1,450 | 412 | [
"DDInter636",
"DDInter632"
] | Empagliflozin | Eluxadoline | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system ... | Moderate | 1 | [
[
[
1450,
24,
412
]
],
[
[
1450,
63,
999
],
[
999,
24,
412
]
],
[
[
1450,
24,
466
],
[
466,
64,
412
]
],
[
[
1450,
63,
1327
],
[
1327,
... | [
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
... | Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Da... |
DB00543 | DB06282 | 87 | 516 | [
"DDInter82",
"DDInter1053"
] | Amoxapine | Levocetirizine | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
87,
24,
516
]
],
[
[
87,
63,
701
],
[
701,
24,
516
]
],
[
[
87,
24,
407
],
[
407,
63,
516
]
],
[
[
87,
24,
1219
],
[
1219,
24,
... | [
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
... | Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may... |
DB00888 | DB14409 | 1,001 | 1,129 | [
"DDInter1133",
"DDInter867"
] | Mechlorethamine | Human adenovirus e serotype 4 strain cl-68578 antigen | A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. The FDA granted marketing approval f... | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
1001,
24,
1129
]
],
[
[
1001,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
1001,
24,
1683
],
[
1683,
24,
1129
]
],
[
[
1001,
63,
134
],
[
134... | [
[
[
"Mechlorethamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Mechlorethamine",
"{u} may lead to a major life threatening interaction when taken with {v... | Mechlorethamine may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Mechlorethamine may cause a moderate interaction that could exacerbate diseases... |
DB11575 | DB11718 | 1,676 | 927 | [
"DDInter841",
"DDInter640"
] | Grazoprevir | Encorafenib | Grazoprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common i... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
1676,
24,
927
]
],
[
[
1676,
63,
1324
],
[
1324,
24,
927
]
],
[
[
1676,
64,
1491
],
[
1491,
24,
927
]
],
[
[
1676,
24,
484
],
[
484,
... | [
[
[
"Grazoprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Grazoprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
... | Grazoprevir may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Grazoprevir may lead to a major life threatening interaction when taken with Midostaurin and Midostaurin m... |
DB00631 | DB09052 | 372 | 250 | [
"DDInter405",
"DDInter220"
] | Clofarabine | Blinatumomab | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostl... | Moderate | 1 | [
[
[
372,
24,
250
]
],
[
[
372,
24,
949
],
[
949,
63,
250
]
],
[
[
372,
24,
637
],
[
637,
24,
250
]
],
[
[
372,
63,
305
],
[
305,
24,... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxo... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Clofarabi... |
DB08896 | DB12010 | 292 | 214 | [
"DDInter1576",
"DDInter785"
] | Regorafenib | Fostamatinib | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
292,
24,
214
]
],
[
[
292,
63,
690
],
[
690,
24,
214
]
],
[
[
292,
40,
79
],
[
79,
24,
214
]
],
[
[
292,
24,
1627
],
[
1627,
24,... | [
[
[
"Regorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Regorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifabutin"
],
[... | Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Regorafenib (Compound) resembles Sorafenib (Compound) and Sorafenib may cause a moderate interaction that could... |
DB11581 | DB14724 | 1,456 | 48 | [
"DDInter1926",
"DDInter634"
] | Venetoclax | Emapalumab | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process,. Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lym... | Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018.[A38676, L4840] The approval of emapalumab was followed by the designation of orphan drug, priority... | Moderate | 1 | [
[
[
1456,
24,
48
]
],
[
[
1456,
64,
362
],
[
362,
24,
48
]
],
[
[
1456,
63,
713
],
[
713,
24,
48
]
],
[
[
1456,
24,
287
],
[
287,
63... | [
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Emapalumab"
]
],
[
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",... | Venetoclax may lead to a major life threatening interaction when taken with Phenytoin and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Emapalumab
Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarat... |
DB00734 | DB09564 | 1,664 | 1,296 | [
"DDInter1605",
"DDInter930"
] | Risperidone | Insulin degludec | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
1664,
24,
1296
]
],
[
[
1664,
63,
274
],
[
274,
23,
1296
]
],
[
[
1664,
24,
1411
],
[
1411,
24,
1296
]
],
[
[
1664,
63,
1645
],
[
1645... | [
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentolamine"
]... | Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine and Phentolamine may cause a minor interaction that can limit clinical effects when taken with Insulin degludec
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide... |
DB00196 | DB11113 | 600 | 657 | [
"DDInter743",
"DDInter307"
] | Fluconazole | Castor oil | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic... | Moderate | 1 | [
[
[
600,
24,
657
]
],
[
[
600,
24,
1079
],
[
1079,
24,
657
]
],
[
[
600,
25,
927
],
[
927,
63,
657
]
],
[
[
600,
25,
540
],
[
540,
2... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
],
[
... | Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Fluconazole may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may ca... |
DB00295 | DB09034 | 475 | 1,313 | [
"DDInter1244",
"DDInter1733"
] | Morphine | Suvorexant | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia. | Major | 2 | [
[
[
475,
25,
1313
]
],
[
[
475,
24,
649
],
[
649,
24,
1313
]
],
[
[
475,
63,
701
],
[
701,
24,
1313
]
],
[
[
475,
24,
971
],
[
971,
... | [
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Suvorexant"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
... | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine... |
DB00365 | DB06723 | 839 | 115 | [
"DDInter842",
"DDInter58"
] | Grepafloxacin | Aluminum hydroxide | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Moderate | 1 | [
[
[
839,
24,
115
]
],
[
[
839,
25,
870
],
[
870,
23,
115
]
],
[
[
839,
24,
355
],
[
355,
23,
115
]
],
[
[
839,
23,
60
],
[
60,
23,
... | [
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fludrocortisone"
],
... | Grepafloxacin may lead to a major life threatening interaction when taken with Fludrocortisone and Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and ... |
DB00853 | DB08880 | 1,686 | 1,510 | [
"DDInter1762",
"DDInter1771"
] | Temozolomide | Teriflunomide | Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alky... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
1686,
25,
1510
]
],
[
[
1686,
63,
1461
],
[
1461,
23,
1510
]
],
[
[
1686,
24,
221
],
[
221,
63,
1510
]
],
[
[
1686,
24,
1136
],
[
1136... | [
[
[
"Temozolomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vita... | Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 ... |
DB09098 | DB15822 | 98 | 69 | [
"DDInter1700",
"DDInter1504"
] | Somatrem | Pralsetinib | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate. Such discussion revolves around whether patients' natural dispo... | Pralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small... | Moderate | 1 | [
[
[
98,
24,
69
]
],
[
[
98,
24,
283
],
[
283,
24,
69
]
],
[
[
98,
63,
1213
],
[
1213,
24,
69
]
],
[
[
98,
63,
609
],
[
609,
25,
... | [
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pralsetinib"
]
],
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
... | Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Pralsetinib
Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib ... |
DB01182 | DB12364 | 371 | 1,421 | [
"DDInter1534",
"DDInter200"
] | Propafenone | Betrixaban | An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Major | 2 | [
[
[
371,
25,
1421
]
],
[
[
371,
24,
1151
],
[
1151,
24,
1421
]
],
[
[
371,
25,
760
],
[
760,
24,
1421
]
],
[
[
371,
64,
888
],
[
888,
... | [
[
[
"Propafenone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Propafenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
],
[
"Sunitinib... | Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Propafenone may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may cause ... |
DB08904 | DB15044 | 375 | 631 | [
"DDInter342",
"DDInter1738"
] | Certolizumab pegol | Tafasitamab | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Tafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of B-cell malignancies. It is produced using recombinant DNA technology in Chinese hamster ovary cells, and contains an IgG1/2 hybrid Fc-domain which has been modified with 2 amino acid substitutions to enhance its cytoto... | Major | 2 | [
[
[
375,
25,
631
]
],
[
[
375,
64,
4
],
[
4,
24,
631
]
],
[
[
375,
25,
270
],
[
270,
24,
631
]
],
[
[
375,
63,
597
],
[
597,
24,
... | [
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tafasitamab"
]
],
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
... | Certolizumab pegol may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Tafasitamab
Certolizumab pegol may lead to a major life threatening interaction when taken with Ocre... |
DB00502 | DB09291 | 1,300 | 741 | [
"DDInter853",
"DDInter1615"
] | Haloperidol | Rolapitant | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Moderate | 1 | [
[
[
1300,
24,
741
]
],
[
[
1300,
24,
506
],
[
506,
24,
741
]
],
[
[
1300,
24,
159
],
[
159,
63,
741
]
],
[
[
1300,
25,
1264
],
[
1264,
... | [
[
[
"Haloperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rolapitant"
]
],
[
[
"Haloperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
... | Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Larotre... |
DB00095 | DB11248 | 66 | 1,193 | [
"DDInter623",
"DDInter1965"
] | Efalizumab | Zinc gluconate | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Zinc gluconate is a zinc salt of gluconic acid comprised of two gluconic acid molecules for each zinc cation (2+). Zinc gluconate is a generally recognized as safe (GRAS) substance by FDA . It is available as a trace mineral supplement and over the counter as a lozenge form for a reduced duration of common colds and wi... | Minor | 0 | [
[
[
66,
23,
1193
]
],
[
[
66,
24,
1096
],
[
1096,
23,
1193
]
],
[
[
66,
24,
725
],
[
725,
62,
1193
]
],
[
[
66,
25,
1259
],
[
1259,
... | [
[
[
"Efalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],... | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Satra... |
DB00562 | DB09038 | 1,014 | 1,450 | [
"DDInter188",
"DDInter636"
] | Benzthiazide | Empagliflozin | Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
1014,
24,
1450
]
],
[
[
1014,
24,
659
],
[
659,
63,
1450
]
],
[
[
1014,
63,
1061
],
[
1061,
24,
1450
]
],
[
[
1014,
24,
1486
],
[
1486... | [
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
... | Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil a... |
DB00395 | DB06691 | 210 | 849 | [
"DDInter301",
"DDInter1155"
] | Carisoprodol | Mepyramine | Originally approved by the FDA in 1959 [FDA label], carisoprodol is a centrally acting muscle relaxant used in painful musculoskeletal conditions in conjunction with physical therapy and other medications. This drug is available by itself in an oral tablet or combined with aspirin, or in a fixed-dose combination with b... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
210,
24,
849
]
],
[
[
210,
63,
1594
],
[
1594,
24,
849
]
],
[
[
210,
24,
272
],
[
272,
24,
849
]
],
[
[
210,
24,
407
],
[
407,
6... | [
[
[
"Carisoprodol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Carisoprodol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
... | Carisoprodol may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Carisoprodol may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine ... |
DB08880 | DB11363 | 1,510 | 1,276 | [
"DDInter1771",
"DDInter39"
] | Teriflunomide | Alectinib | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes prol... | Major | 2 | [
[
[
1510,
25,
1276
]
],
[
[
1510,
64,
305
],
[
305,
24,
1276
]
],
[
[
1510,
25,
637
],
[
637,
24,
1276
]
],
[
[
1510,
25,
1476
],
[
1476,
... | [
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alectinib"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"A... | Teriflunomide may lead to a major life threatening interaction when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Teriflunomide may lead to a major life threatening interaction when taken with Asparagi... |
DB00372 | DB00402 | 999 | 1,407 | [
"DDInter1793",
"DDInter685"
] | Thiethylperazine | Eszopiclone | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia. It is the active stereoisomer of zopiclone, belonging to the class of drugs known as _cyclopyrrolones_.[A179638,L6850] Cyclopyrrolone drugs demonstrate high efficacy and low toxicity, offering a ... | Moderate | 1 | [
[
[
999,
24,
1407
]
],
[
[
999,
24,
1264
],
[
1264,
63,
1407
]
],
[
[
999,
63,
1242
],
[
1242,
24,
1407
]
],
[
[
999,
25,
593
],
[
593,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eszopiclone"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Eszopiclone
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and... |
DB00065 | DB01004 | 581 | 563 | [
"DDInter923",
"DDInter806"
] | Infliximab | Ganciclovir | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. | Major | 2 | [
[
[
581,
25,
563
]
],
[
[
581,
25,
248
],
[
248,
40,
563
]
],
[
[
581,
25,
36
],
[
36,
63,
563
]
],
[
[
581,
25,
613
],
[
613,
24,
... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ganciclovir"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Valganciclovir"
],
[
"Valganciclovir",
... | Infliximab may lead to a major life threatening interaction when taken with Valganciclovir and Valganciclovir (Compound) resembles Ganciclovir (Compound)
Infliximab may lead to a major life threatening interaction when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when... |
DB00945 | DB06822 | 1,479 | 802 | [
"DDInter20",
"DDInter1812"
] | Acetylsalicylic acid | Tinzaparin | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for h... | Major | 2 | [
[
[
1479,
25,
802
]
],
[
[
1479,
23,
944
],
[
944,
62,
802
]
],
[
[
1479,
24,
222
],
[
222,
24,
802
]
],
[
[
1479,
63,
383
],
[
383,
... | [
[
[
"Acetylsalicylic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tinzaparin"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
... | Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Tinzaparin
Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Sibutra... |
DB00261 | DB06176 | 702 | 1,342 | [
"DDInter93",
"DDInter1616"
] | Anagrelide | Romidepsin | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Major | 2 | [
[
[
702,
25,
1342
]
],
[
[
702,
23,
1247
],
[
1247,
23,
1342
]
],
[
[
702,
24,
336
],
[
336,
24,
1342
]
],
[
[
702,
25,
956
],
[
956,
... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Romidepsin"
]
],
[
[
"Anagrelide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfam... | Anagrelide may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine an... |
DB06273 | DB09322 | 980 | 1,114 | [
"DDInter1824",
"DDInter1966"
] | Tocilizumab | Zinc sulfate | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Zinc sulfate is the inorganic compound with the formula ZnSO4 and historically known as "white vitriol". It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system. | Minor | 0 | [
[
[
980,
23,
1114
]
],
[
[
980,
63,
66
],
[
66,
23,
1114
]
],
[
[
980,
64,
1057
],
[
1057,
23,
1114
]
],
[
[
980,
25,
259
],
[
259,
... | [
[
[
"Tocilizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
]
],
[
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
... | Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Tocilizumab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may caus... |
DB00367 | DB06168 | 566 | 1,531 | [
"DDInter1061",
"DDInter281"
] | Levonorgestrel | Canakinumab | Levonorgestrel (LNG) is a synthetic progestogen similar to [Progesterone] used in contraception and hormone therapy.[A181988,T659] Also known as Plan B, it is used as a single agent in emergency contraception, and as a hormonal contraceptive released from an intrauterine device, commonly referred to as an IUD. Some of ... | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Moderate | 1 | [
[
[
566,
24,
1531
]
],
[
[
566,
1,
873
],
[
873,
24,
1531
]
],
[
[
566,
24,
1362
],
[
1362,
63,
1531
]
],
[
[
566,
25,
1476
],
[
1476,
... | [
[
[
"Levonorgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Levonorgestrel",
"{u} (Compound) resembles {v} (Compound)",
"Norgestimate"
],
[
"Norgestimate",
"{u} may ca... | Levonorgestrel (Compound) resembles Norgestimate (Compound) and Norgestimate may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Levonorgestrel may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction t... |
DB00026 | DB01157 | 1,184 | 304 | [
"DDInter94",
"DDInter1875"
] | Anakinra | Trimetrexate | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect. | Moderate | 1 | [
[
[
1184,
24,
304
]
],
[
[
1184,
24,
58
],
[
58,
24,
304
]
],
[
[
1184,
24,
1270
],
[
1270,
63,
304
]
],
[
[
1184,
63,
305
],
[
305,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimetrexate"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Trimetrexate
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified prote... |
DB00679 | DB00771 | 684 | 262 | [
"DDInter1796",
"DDInter397"
] | Thioridazine | Clidinium | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | Moderate | 1 | [
[
[
684,
24,
262
]
],
[
[
684,
24,
1511
],
[
1511,
63,
262
]
],
[
[
684,
63,
19
],
[
19,
24,
262
]
],
[
[
684,
40,
508
],
[
508,
24,... | [
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clidinium"
]
],
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
... | Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Clidinium
Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and ... |
DB01242 | DB01259 | 1,237 | 392 | [
"DDInter410",
"DDInter1024"
] | Clomipramine | Lapatinib | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
1237,
24,
392
]
],
[
[
1237,
6,
4973
],
[
4973,
45,
392
]
],
[
[
1237,
21,
28688
],
[
28688,
60,
392
]
],
[
[
1237,
62,
112
],
[
112,
... | [
[
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Clomipramine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)"... | Clomipramine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound)
Clomipramine (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Lapatinib (Compound)
Clomipramine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and M... |
DB00468 | DB00496 | 1,424 | 194 | [
"DDInter1557",
"DDInter480"
] | Quinine | Darifenacin | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention. It is unknown if M3 receptor ... | Moderate | 1 | [
[
[
1424,
24,
194
]
],
[
[
1424,
64,
576
],
[
576,
1,
194
]
],
[
[
1424,
25,
543
],
[
543,
63,
194
]
],
[
[
1424,
6,
4304
],
[
4304,
... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darifenacin"
]
],
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methadone"
],
[
"Methadone",
... | Quinine may lead to a major life threatening interaction when taken with Methadone and Methadone (Compound) resembles Darifenacin (Compound)
Quinine may lead to a major life threatening interaction when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00361 | DB11793 | 134 | 738 | [
"DDInter1939",
"DDInter1297"
] | Vinorelbine | Niraparib | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
134,
24,
738
]
],
[
[
134,
24,
1033
],
[
1033,
63,
738
]
],
[
[
134,
24,
663
],
[
663,
24,
738
]
],
[
[
134,
63,
1253
],
[
1253,
... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
],
[
... | Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Metho... |
DB00865 | DB09080 | 939 | 144 | [
"DDInter187",
"DDInter1331"
] | Benzphetamine | Olodaterol | A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222) | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
939,
24,
144
]
],
[
[
939,
40,
371
],
[
371,
24,
144
]
],
[
[
939,
1,
1301
],
[
1301,
24,
144
]
],
[
[
939,
63,
1445
],
[
1445,
... | [
[
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Benzphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Propafenone"
],
[
"Propafenone",
"{u} may cause a... | Benzphetamine (Compound) resembles Propafenone (Compound) and Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Benzphetamine (Compound) resembles Levacetylmethadol (Compound) and Levacetylmethadol may cause a moderate interaction that could exacerbate diseases when ... |
DB00836 | DB06176 | 543 | 1,342 | [
"DDInter1088",
"DDInter1616"
] | Loperamide | Romidepsin | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
543,
24,
1342
]
],
[
[
543,
24,
112
],
[
112,
23,
1342
]
],
[
[
543,
24,
956
],
[
956,
24,
1342
]
],
[
[
543,
63,
485
],
[
485,
... | [
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[... | Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin and N... |
DB00095 | DB12001 | 66 | 564 | [
"DDInter623",
"DDInter7"
] | Efalizumab | Abemaciclib | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | Moderate | 1 | [
[
[
66,
24,
564
]
],
[
[
66,
24,
748
],
[
748,
24,
564
]
],
[
[
66,
63,
58
],
[
58,
24,
564
]
],
[
[
66,
24,
151
],
[
151,
63,
... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
],
... | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine and Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Alefacept ... |
DB00364 | DB09100 | 417 | 320 | [
"DDInter1717",
"DDInter1799"
] | Sucralfate | Thyroid, porcine | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protect... | Thyroid extract is dried and powdered thyroid glands from pigs containing tiiodothyronine (T3) and thyroxine (T4) used to supplement low or absent thyroid activity.[A190831,L11755] Thyroid extract has been described in literature to treat hypothyroidism since 1891 but its use dates back as far as the 6th century. Thyro... | Minor | 0 | [
[
[
417,
23,
320
]
],
[
[
417,
24,
127
],
[
127,
24,
320
]
],
[
[
417,
63,
1324
],
[
1324,
24,
320
]
],
[
[
417,
24,
1296
],
[
1296,
... | [
[
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglitol"
],
[
... | Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Tr... |
DB00761 | DB00985 | 1,621 | 1,443 | [
"DDInter1497",
"DDInter562"
] | Potassium chloride | Dimenhydrinate | A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives. The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium p... | Dimehydrinate was first described in the literature in 1949, and patented in 1950. Early research into dimenhydrinate focused on its role as an antihistamine for urticaria; the treatment of motion sickness was an accidental discovery. Dimenhydrinate, also known as B-dimethylaminoethyl benzohydrol ether 8-chlorotheophyl... | Major | 2 | [
[
[
1621,
25,
1443
]
],
[
[
1621,
25,
1376
],
[
1376,
63,
1443
]
],
[
[
1621,
64,
357
],
[
357,
1,
1443
]
],
[
[
1621,
25,
358
],
[
358,
... | [
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dimenhydrinate"
]
],
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diphenhydramine"
],
[
"... | Potassium chloride may lead to a major life threatening interaction when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Dimenhydrinate
Potassium chloride may lead to a major life threatening interaction when taken with Benzatropine and Benz... |
DB00014 | DB13928 | 521 | 1,385 | [
"DDInter839",
"DDInter1660"
] | Goserelin | Semaglutide | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
521,
24,
1385
]
],
[
[
521,
25,
1154
],
[
1154,
24,
1385
]
],
[
[
521,
24,
1399
],
[
1399,
63,
1385
]
],
[
[
521,
24,
872
],
[
872,
... | [
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
],
[
"Pasireotid... | Goserelin may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithium carbo... |
DB00352 | DB04865 | 482 | 4 | [
"DDInter1814",
"DDInter1335"
] | Tioguanine | Omacetaxine mepesuccinate | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Moderate | 1 | [
[
[
482,
24,
4
]
],
[
[
482,
25,
770
],
[
770,
24,
4
]
],
[
[
482,
24,
496
],
[
496,
63,
4
]
],
[
[
482,
63,
66
],
[
66,
24,
4... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Tioguanine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
... | Tioguanine may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine... |
DB00270 | DB09098 | 1,428 | 98 | [
"DDInter993",
"DDInter1700"
] | Isradipine | Somatrem | Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affini... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
1428,
24,
98
]
],
[
[
1428,
1,
336
],
[
336,
24,
98
]
],
[
[
1428,
24,
159
],
[
159,
63,
98
]
],
[
[
1428,
24,
1573
],
[
1573,
2... | [
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Isradipine",
"{u} (Compound) resembles {v} (Compound)",
"Nifedipine"
],
[
"Nifedipine",
"{u} may cause a moderate ... | Isradipine (Compound) resembles Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that c... |
DB00010 | DB09038 | 1,649 | 1,450 | [
"DDInter1661",
"DDInter636"
] | Sermorelin | Empagliflozin | Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
1649,
24,
1450
]
],
[
[
1649,
24,
1179
],
[
1179,
24,
1450
]
],
[
[
1649,
24,
1296
],
[
1296,
63,
1450
]
],
[
[
1649,
24,
1179
],
[
11... | [
[
[
"Sermorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Sermorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
... | Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Insulin de... |
DB00585 | DB11732 | 1,127 | 1,097 | [
"DDInter1309",
"DDInter1027"
] | Nizatidine | Lasmiditan | A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers. | Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. [sumatriptan]) have se... | Moderate | 1 | [
[
[
1127,
24,
1097
]
],
[
[
1127,
24,
478
],
[
478,
24,
1097
]
],
[
[
1127,
1,
1194
],
[
1194,
24,
1097
]
],
[
[
1127,
25,
1250
],
[
1250,... | [
[
[
"Nizatidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Nizatidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
... | Nizatidine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Nizatidine (Compound) resembles Ranitidine (Compound) and Ranitidine may cause a moderate interaction that could e... |
DB00434 | DB01403 | 13 | 9 | [
"DDInter459",
"DDInter1175"
] | Cyproheptadine | Methotrimeprazine | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Moderate | 1 | [
[
[
13,
24,
9
]
],
[
[
13,
24,
1178
],
[
1178,
40,
9
]
],
[
[
13,
24,
1164
],
[
1164,
1,
9
]
],
[
[
13,
24,
401
],
[
401,
24,
... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperaz... | Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Methotrimeprazine (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine (Compound) res... |
DB09472 | DB11837 | 1,383 | 1,297 | [
"DDInter1693",
"DDInter1351"
] | Sodium sulfate | Osilodrostat | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
1383,
24,
1297
]
],
[
[
1383,
63,
222
],
[
222,
23,
1297
]
],
[
[
1383,
63,
623
],
[
623,
24,
1297
]
],
[
[
1383,
24,
657
],
[
657,
... | [
[
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
... | Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine ... |
DB00559 | DB14723 | 152 | 159 | [
"DDInter223",
"DDInter1026"
] | Bosentan | Larotrectinib | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
152,
24,
159
]
],
[
[
152,
24,
222
],
[
222,
23,
159
]
],
[
[
152,
24,
741
],
[
741,
24,
159
]
],
[
[
152,
63,
63
],
[
63,
24,
... | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant and Rolapit... |
DB08880 | DB14962 | 1,510 | 1,363 | [
"DDInter1771",
"DDInter1847"
] | Teriflunomide | Trastuzumab deruxtecan | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes i... | Major | 2 | [
[
[
1510,
25,
1363
]
],
[
[
1510,
63,
1430
],
[
1430,
24,
1363
]
],
[
[
1510,
25,
384
],
[
384,
24,
1363
]
],
[
[
1510,
64,
599
],
[
599,
... | [
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab deruxtecan"
]
],
[
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
... | Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab deruxtecan
Teriflunomide may lead to a major life threatening interaction when taken with Idelalisib and... |
DB00563 | DB15762 | 663 | 725 | [
"DDInter1174",
"DDInter1644"
] | Methotrexate | Satralizumab | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to [tocilizumab], which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare au... | Moderate | 1 | [
[
[
663,
24,
725
]
],
[
[
663,
24,
1362
],
[
1362,
24,
725
]
],
[
[
663,
63,
134
],
[
134,
24,
725
]
],
[
[
663,
25,
629
],
[
629,
2... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Satralizumab"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vin... |
DB09036 | DB09237 | 812 | 1,586 | [
"DDInter1668",
"DDInter1045"
] | Siltuximab | Levamlodipine | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). I... | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlod... | Moderate | 1 | [
[
[
812,
24,
1586
]
],
[
[
812,
64,
908
],
[
908,
24,
1586
]
],
[
[
812,
63,
1184
],
[
1184,
24,
1586
]
],
[
[
812,
63,
467
],
[
467,
... | [
[
[
"Siltuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
]
],
[
[
"Siltuximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
],
[
"Golimuma... | Siltuximab may lead to a major life threatening interaction when taken with Golimumab and Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Siltuximab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a m... |
DB01234 | DB09065 | 1,220 | 760 | [
"DDInter513",
"DDInter424"
] | Dexamethasone | Cobicistat | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Moderate | 1 | [
[
[
1220,
24,
760
]
],
[
[
1220,
63,
479
],
[
479,
23,
760
]
],
[
[
1220,
23,
271
],
[
271,
23,
760
]
],
[
[
1220,
25,
907
],
[
907,
... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
... | Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabe... |
DB00835 | DB04953 | 100 | 495 | [
"DDInter245",
"DDInter708"
] | Brompheniramine | Ezogabine | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients wi... | Moderate | 1 | [
[
[
100,
24,
495
]
],
[
[
100,
74,
662
],
[
662,
24,
495
]
],
[
[
100,
24,
1264
],
[
1264,
24,
495
]
],
[
[
100,
63,
13
],
[
13,
24,... | [
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ezogabine"
]
],
[
[
"Brompheniramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases whe... | Brompheniramine (Compound) resembles Carbinoxamine (Compound) and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Ezogabine
Brompheniramine may cause a moderate... |
DB00361 | DB00526 | 134 | 1,555 | [
"DDInter1939",
"DDInter1355"
] | Vinorelbine | Oxaliplatin | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Moderate | 1 | [
[
[
134,
24,
1555
]
],
[
[
134,
63,
141
],
[
141,
24,
1555
]
],
[
[
134,
24,
79
],
[
79,
24,
1555
]
],
[
[
134,
24,
810
],
[
810,
63... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Floxuridine"
],
... | Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine and Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and So... |
DB00544 | DB10795 | 970 | 221 | [
"DDInter757",
"DDInter1486"
] | Fluorouracil | Poliovirus type 1 antigen (formaldehyde inactivated) | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a c... | Moderate | 1 | [
[
[
970,
24,
221
]
],
[
[
970,
64,
581
],
[
581,
24,
221
]
],
[
[
970,
63,
599
],
[
599,
24,
221
]
],
[
[
970,
24,
384
],
[
384,
24,... | [
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Fluorouracil",
"{u} may lead to a major life threatening interaction when taken with {v}",
... | Fluorouracil may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Fluorouracil may cause a moderate interaction that could exacerbate diseases when t... |
DB00556 | DB09340 | 1,262 | 1,013 | [
"DDInter1429",
"DDInter1895"
] | Perflutren | Tyropanoic acid | Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultras... | Tyropanoic acid is a radiocontrast agent used in cholecystography, the X-ray diagnosis of gallstones under the trade names include Bilopaque, Lumopaque, Tyropaque, and Bilopac. The molecule contains three heavy iodine atoms which obstruct X-rays in the same way as the calcium in bones, which results in a visible image ... | Moderate | 1 | [
[
[
1262,
24,
1013
]
],
[
[
1262,
24,
1264
],
[
1264,
23,
857
],
[
857,
23,
1013
]
],
[
[
1262,
24,
278
],
[
278,
62,
857
],
[
857,
23,
... | [
[
[
"Perflutren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tyropanoic acid"
]
],
[
[
"Perflutren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a minor interaction that can limit clinical effects when taken with Cholestyramine and Cholestyramine may cause a minor interaction that can limit clinical effects when taken with Tyropanoic acid
Per... |
DB00188 | DB00641 | 168 | 467 | [
"DDInter222",
"DDInter1675"
] | Bortezomib | Simvastatin | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endog... | Moderate | 1 | [
[
[
168,
24,
467
]
],
[
[
168,
6,
8374
],
[
8374,
45,
467
]
],
[
[
168,
18,
2642
],
[
2642,
46,
467
]
],
[
[
168,
7,
2507
],
[
2507,
... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
]
],
[
[
"Bortezomib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Bortezomib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Simvastatin (Compound)
Bortezomib (Compound) downregulates PAN2 (Gene) and PAN2 (Gene) is upregulated by Simvastatin (Compound)
Bortezomib (Compound) upregulates NR1H2 (Gene) and NR1H2 (Gene) is upregulated by Simvastatin (Compound)
Bortezomib (Com... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.